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Summary
The tumor necrosis factor a (TNF-a) gene was introduced by retroviral gene transfer into the
TNF-a-insensitive tumor cell line J558L . Production of 40 pg/ml TNF-a by clone J2T12
consistently did not change the growth rate in vitro, but drastically suppressed tumor growth
when injected into syngeneic BALB/c mice. Within 2 wk, 90% of the mice inoculated with
J558L cells developed a tumor, but none of the mice injected with J2T12 did so. Within the
observation period (>3 mo), 60% of the mice inoculated with J2T12 did not develop a tumor.
In the other 40% of the mice, tumor manifestation was significantly delayed. Mice injected
simultaneously withJ2T12 cells and an antiTNF-a monoclonal antibody developed tumors similar
to parental J558L cells. Similarly, the tumor-suppressive effects ofTNF-a were abolished, e.g.,
by injection of an anti-type 3 complement receptor (CR3) monoclonal antibody that is known
to prevent migration ofinflammatory cells. These results and the observation oftumor-infiltrating
macrophages suggest that lack of tumorigenicity ofJ2T12 cells is due to the TNF-ac secretion
by the tumor cells and that TNF-a acts indirectly by a mechanism that involves chemotactic
recruitment and activation of cells, predominantly ofmacrophages. In contrast, the tumor growth
was not affected when, instead ofTNF-a, interleukin 6 was expressed by J558L cells . Together,
our results support the concept of tumor cell-targeted rytokine gene transfer as a tool for cancer
treatment, and particularly demonstrate that extremely low doses ofTNF-ca produced by tumor
cells are sufficient to inhibit tumor growth without detectable side effects .
A pplication of cytokines has already been promising in
cancer treatment (1) . However, it reveals a severe problem
resulting from the requirement to apply systematically high
doses of the respective cytokines. Application of therapeuti-
cally effective concentrations is often accompanied by toxic
side effects. This problem may be circumvented by "tumor
cell-targeted rytokine gene therapy" (2) : the tumor cells are
genetically engineered to produce a given cytokine in vitro
and upon injection into mice provide a locally enhanced
rytokine concentration . This makes use ofamore physiolog-
icalmode of action of the cytokine to eventually chemotacti-
cally attract effector cells and/or induce a tumor-specific im-
mune response . Additionally, upon destruction of the tumor
cells, the source for the cytokine production is eliminated .
Tumor cell-targeted rytokine gene therapy has been success-
fully used with Ilr2, 114, and IFN-'Y genes (3-7) . These ex-
periments demonstrate that in certain cases the failure of the
immune system to recognize the tumor cells is due to
insufficient activation rather than to the lack of immuno-
genic determinants on the tumor cells .
The antitumor activity of TNF-ct is well documented (for
review, see 8) . Originally, it was attributed to a direct cyto-
lytic effect on tumors. Accordingly, in most studies the effect
ofsystemical application ofTNF-a on in vitro sensitive tumor
cell lines has been investigated. Recently, it has become clear
that some effects ofTNF-a are mediated by immunological
effector mechanisms {9) . Tumor-suppressive effects were ob-
tained only with nearly lethal concentrations of systemically
applied TNF-a . Furthermore, the systemic application of
TNF-a does not make use: (a) of the property of TNF-a
to induce chemotactic attraction of macrophages (10) and,
consequently, (b) ofthe potential of macrophages to display
a tumoricidal activity (11-13) .
We have investigated the potential ofTNF-a to suppress
the growth of a TNF-a-insensitive tumor cell line. There-
fore, the TNF-a gene was expressed in a tumor cell line in
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destroy the tumor cells.
Materials and Methods
CellLines.
￿
J558L is a heavy chain loss variant ofBALB/c-derived
plasmacytoma J558 (14) and was maintained as described (4). Cell
cultivation conditions ofvirus-packaging cell lines PA317 (15) and
psi2 (16) were described (4).
mAbs.
￿
The rat anti-mouse TNF-a mAb (IgM/K) was pur-
chased from Innogenetics, Antwerpen, Belgium (no. IKM-90) and
contained 1.6 x 106 U/ml. 1 U was defined as the amount of an-
tibody required for 50% neutralization of 1 U TNF-a in the L929
cytotoxic assay. Control antibody was the isotype-matched mAb
23-233 (unpublished results). 5C6 is a mAb (IgG/K) directed against
the type 3 complement receptor (CR3) (17). All mAbs were used
as ascites fluid.
Retroviral TNF-a Gene Transfer andExpression inJ558L Cells.
￿
A
1-kb Sall fragment ofplasmid pSVd2-3mTNF (18), whichcontains
the mouse TNF-cY cDNA minus most of the 3' untranslated re-
gion, was inserted into the Xhol restriction site ofplasmid pXT1
(19) resulting in pXT-TNF. In pXT-TNF, the TNF-a gene is ex-
pressed by the thymidine kinase promotor and the neomycin gene
as a selectable marker by the retroviral long terminal repeat
(LTR)t. PA317 cells were transfected by calcium-phosphate
coprecipitation as described (4), selected in G418 (1 mg/ml)-
containing medium, and clones were established. Subsequently, psi2
cells were infected with culture supernatant of clone PA317-XT-
TNF, selected in G418 (1 mg/ml)-containing medium, and finally
clone psi-XT-TNF was established, which produces a viral titer
equivalent to 5 x 105 G418R colonies/ml. Retroviral infection and
determination of the viral titer was done as described (4). The virus-
containing supernatant of psi-XT-TNF was used to infect 106
J558L cells. After 14 d, selection in G418 (1 mg/ml) clones were
established. TNF-a activity was measured by the L929 cytotoxic
assay as described (20). 1 U was defined as the amount of TNF-a
required for 50% cytolysis. In our assay system, 1 U TNF-cY ac-
tivity corresponded to 30 pg/ml.
IL6 Gene Transferand Expression inJ558L Cells.
￿
A 670-bp frag-
ment of plasmid pHPlB5 (21) containing the mouse IL-6 cDNA
coding region up to the translational stop signal was inserted into
the Bg1II cloning site of plasmid pEB.B splice-neo by the use of
appropriate oligonucleotides resulting in pEP.B-IL6. pEB.B splice-
neo is an expression vector that allows expression of genes by the
Ig heavy chain (IgH) enhancer/promoter (W Mtiller and T.
Blankenstein, unpublished results). 5 x 106 J558L cells were
transfected with pEP.B-IL6 plasmid DNA by electroporation as
described (22) . Transfected cells were selected in 1 mg/ml G418-
containing medium and clones were established. The biological ac-
tivity of IL6 was measured by proliferation of the mouse plasmacy-
toma cell line TEPC 1033 (23) as described (24). 1 U was defined
as the amount of IL6 required for half-maximal proliferation.
Analysis ofTumor Cell Growth.
￿
5 x 106 cells were injected sub-
cutaneously into 6-wk-old female BALB/c mice (Bomholtgard, Den-
mark). Mice bearing a tumor of>0.5 cm in diameter were consid-
ered as positive. To study the tumor growth in the presence of
mAbs, 0.1 ml mAb was coinjected with the cells and a further
0.1 ml was injected on days 2, 4, 6, and 8 either intraperitoneally
(5C6) or intravenously (TNF-a and control mAb). In some ex-
periments, 100 mg/kg body weight Zymosan (Serva, Heidelberg,
1 Abbreviation used in this paper. LTR, long terminal repeat.
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FRG) was injected intraperitoneally the day before the tumor cells
were injected subcutaneously.
Immunohistochemistry.
￿
Indirect immunoenzymatic staining of
6-Am frozen sections was performed by using the anti-CR3 mono-
clonal primary antibody MAC-1(25) and alkaline phosphatase-con-
jugated secondary and tertiary antibodies. Alkaline phosphatase ac-
tivity was visualized by New Fuchsin as described (26), and sections
were counterstained by hemalaun.
Results
TNF-a and IL6 Gene Transfer and Expression in Myeloma
J558L. Theexperimental approach for the study ofthe tumor
cell-targeted TNF-a gene therapy is outlined in Fig. 1. A
TNF-a-specific retroviral vector (pXT-TNF) was constructed,
expressing the neomycin gene as a selectable marker by the
retroviral LTR, and the TNF-a gene by the internal thymi-
dine kinase promoter. Virus-producing cells were generated
and, subsequently, J558L cells were infected, selected for
G418R, and cloned. Two clones, J2T12 and J2T4, were as-
sayed for TNF-a activity in the culture supernatant three times
in intervals of 6 wk. The cells produced 40 pg/ml (J2T12)
and 14 pg/ml (J2T4) on the average. The activity did not
decrease during culturing. The biological activity in the cul-
ture supernatant of J2T12 cells could be neutralized by an
antiTNF-a mAb. Determination of the doubling time showed
no difference between J2T12 and parentalJ558L cells. Addi-
tionally, in a proliferation assay with J558L cells in the pres-
ence of increasing amounts of TNF-a up to 100 ng/ml, we
did not observe cytostatic or cytolytic effects on J558L cells
(data not shown). Therefore, the TNF-a productionbyJ558L
cells does not change the growth rate ofthe cells, and J558L
cells are resistant to TNF-a in vitroeven in a 2,500-fold higher
concentration than produced by J2T12 cells. In parallel ex-
periments, the IIr6 gene was expressed inJ558L cells. There-
fore, a plasmid was constructed that contains the mouse 11,6
cDNA region under the transcriptional control of the IgH
enhancer/promoter (pEP-IL6). J558L cells were transfected
by electroporation with pEP-IL6, and finally a clone was es-
tablished 0558-IIr6) that produces 500 U/ml IL6 as deter-
mined by the TEPC 1033 indicator line (data not shown).
The Growth of TNF-a- but not IL6producing J558L Cells
Is Suppressed In Viva The tumor progression ofJ2T12 cells
in comparison to J558-IL6 and parental J558L cells was moni-
tored (Fig. 2). 5 x 106 of either cells were injected sub-
cutaneously into syngeneic BALB/c mice. After 2 wk, 90%
(45/50) of the mice injected with J558L cells had developed
a tumor. 100% (30/30) of the mice injected with J558LIL6
had developed a tumor within 10 d. In contrast, 60% (18/30)
of the mice inoculated with J2T12 cells did not develop a
tumor during the observation of >3 mo. In the other 40%
(12/30), the tumor growth was delayed, the first mice de-
veloping a tumor after 4 wk. Similar results were obtained
with the second clone, J2T4, but J558L cells infected with
a control virus (pXT1) grew as a tumor, like the parental
cells (data not shown) .
To analyze possible toxic side effects of the TNF-a secreted
by J2T12 cells, mice injected with J2T12 cells were weighedFigure 1 .
￿
Experimental approach for the study of TNF-a-mediated
tumor suppression. LTR, long terminal repeat ; TK-P, herpes simplex
virus-derived thymidine kinasepromotor; SD, splice donor site; (SA), cryptic
splice acceptor site; X, XhoI ; S, Sall .
and compared with naive mice or mice injected with J558L
cells, since high amounts ofTNF-a areknown to cause drastic
weight loss (27) . We could neither observe a significant weight
loss in J2T12-injected mice, nor did they show any obvious
symptoms of cachexia .
mAbs against both, TNF-a and CR3 Revert the Phenotype
ofJ2T12 Cells. BALB/c mice were injected withJ2T12 cells
(5 x 106 cells/mouse) simultaneously with an anti-TNF-a
mAb and, as control, with an isotype-matched mAb. 80%
(4/5) of the mice treated with the antiTNF-a mAb devel-
oped a tumor within 20 d, but only 20% (1/5) of the mice
that had been treated with the control mAb did (Fig . 3) .
Subsequently, the tumor-suppressing mechanism induced by
TNF-a was analyzed . J2T12 cells were injected subcutane-
ously into BALB/c mice simultaneously with 5C6, an anti-
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Figure 2 .
￿
Kinetic of tumor progression in BALB/c mice injected sub-
cutaneously with 5 x 106 J558L (O), J558-IL6 (*), or J2T12 (A) cells .
50 J558L, 30 J558-IL6, and 30 J2T12 cell-injected mice were analyzed .
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CR3 mAb that is known to block migration of inflamma-
tory cells such as macrophages, neutrophils, orNK cells (17) .
As can be seen from Fig. 3, mAb 5C6 completely abolished
tumor suppression . Consistently, injection ofZymosan, which
is known to induce an inflammatory process, reversed the
nontumorigenic phenotype of J2T12 cells (Fig. 3) when it
was injected intraperitoneally the day before mice received
J2T12 cells subcutaneously.
Macrophage Infiltration at the Tumor Site Induced by TNF-u.
The observation that the anti-CR3 mAb neutralized the an-
titumor activity ofTNF-a suggests that the tumor suppres-
sion acts indirectly via CR3+ cells of the host . To demon-
strate cellular infiltration at the tumor site and to identify
the respective cells, immunohistochemical analysis was per-
formed . BALB/c mice were injected subcutaneously with 5 x
106 J2T12 or J558L cells . Tissue from the injection site was
excised at different time points and stained with amAb against
CR3 . CR3+ cells, morphologically identified as macro-
phages, were visible in mice injected withJ2T12 cells on day
2 (Fig. 4) and increased to a massive infiltrate on day 5 . In
contrast, in tissue sections derived from mice injected with
J558L cells, moderate infiltration consisting predominantly
of granulocytes could be observed .
Discussion
The severe toxicity of high concentrations of systemically
applied cytokines and the well-established fact that cytokines,
under physiological conditions, act locally and in a narrow
range necessitates the need to findnew eacperimental approaches
for immunotherapy in cancer. These criteria are met by tumor
cell-targeted cytokine gene therapy, which is achieved by
transfer and expression ofappropriate genes into tumor cells
in vitro followed by the analysis of their growth characteris-
tics in vivo. This approach provides a sensitive assay : (a) to
detect the antitumor activity of cytokines ; (b) to titrate
cytokine concentrations required to exert antitumor activity
without toxic side effects; (c) to elucidate the type of tumor
cells that are susceptible or resistant for cytokine gene therapy ;
Figure 3 .
￿
Kinetic of tumor progression in BALB/c mice injected sub-
cutaneously with 5 x 106 J2T12 cells and simultaneously with an anti-
CR31 receptormAb (O), an antiTNF-amAb (A), a controlmAb
or zymosan (*) . There were five mice per group.1050
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tivity ofcytokines operate and, finally; (e) to analyze whether
different cytokines cooperate or synergize in their properties
to induce a tumor-specific immune response.
Several arguments underline the importance of thoroughly
studying rytokine-mediated tumor suppression. The delete-
rious consequences of aberrant rytokine production acting
in an autocrine or paracrine manner have been shown in a
number of studies (28) . The tumor cell-targeted rytokine
gene therapy studied so far indicated that different cytokines
induce different tumor-specificimmune responses . For instance,
IL2 produced by tumor cells seems to act primarily by
bypassing T helper cell function and inducing a cytotoxic
T lymphocyte response (6), whereas IL4, when secreted by
tumor cells, induces (at least partially) a T cell-independent
immune response (3, 4) . The main anti-tumor effector cells
induced by IL-4 are thought to be eosinophils and macro-
phages. Moreover, some tumor cell types seem to be more
susceptible to IL4 treatment than others. In another study,
IFN-y produced by tumor cells induced a tumor-specific im-
mune response involving mainly CTL but not activated mac-
rophages (7) . We have investigated tumor cell-targeted
rytokine gene therapy with TNF-a and 11,6 genes in the
mouse plasmacytoma J558L . The IL6 expression by J558L
cells did not show any sign of tumor suppression . In con-
trast, tumor growth seemed slightly accelerated, confirming
the growth-promoting activity ofIL6 for plasmacytomas (23) .
These results are not necessarily in contrast to the recently
described antitumor activity of IL-6 on a variety of tumor
cells (29), but demonstrate the requirement to test different
tumorcells types for their susceptibility to different cytokines .
The expression of TNF-a instead of IL6 by J558L cells
strongly suppressed the tumor growth, allowing the following
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